Clinical trials: Berger Disease
IgA Nephropathy, Berger Disease
Atacicept in Subjects With IgA Nephropathy
A Phase 3 Study with Atacicept in Subjects With IgA Nephropathy (ORIGIN 3)
- Trial name
- ORIGIN 3 (NCT04716231)
- Testing
- Atacicept
- Where
- United States
- Volunteers
- 428 people
- Sponsor
- Vera Therapeutics, Inc.
IgA Nephropathy (IgAN), Berger Disease
A Study of Cemdisiran in Adults With Immunoglobulin A Nephropathy (IgAN)
The purpose of this study is to evaluate the effect of cemdisiran on proteinuria in adults with immunoglobulin A nephropathy (IgAN), who excrete >1 gram (gm) of protein per day despite standard of care, which includes treatment…
- Conditions
- IgA Nephropathy (IgAN), Berger Disease, Glomerulonephritis, IgA
- Trial name
- NCT03841448
- Testing
- Cemdisiran
- Where
- 17 sites in Canada, France and 7 more
- Volunteers
- 31 people
- Sponsor
- Alnylam Pharmaceuticals